Phase II Study of Lenvatinib in Patients With Progressive, Recurrent or Metastatic Adenoid Cystic Carcinoma Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Laryngeal Neoplasms
  • Neoplasms, Squamous Cell

abstract

  • This trial met the prespecified overall response rate primary end point, demonstrating antitumor activity with lenvatinib in R/M ACC patients. Toxicity was comparable to previous studies, requiring monitoring and management.

publication date

  • June 20, 2019

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.18.01859

PubMed ID

  • 30939095

Additional Document Info

start page

  • 1529

end page

  • 1537

volume

  • 37

number

  • 18